Skip to content

A Clinical trial to study the safety and efficacy of â??Pachaikarpoora Vadagamâ?? (internal) and â??Vaeppa Ennaiâ?? (External) in the treatment of Osteoarthritis-knee joint.

An open clinical trial to evaluate the safety and efficacy of Siddha mineroherbal formulation Pachaikarpoora Vadagam(internal) and Vaeppa ennai(external) in the management of Azhal Keel Vayu(Osteoarthritis-Knee joint)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/06/014441
Enrollment
40
Registered
2018-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: Pachaikarpoora Vadagam and Vaeppa Ennai: Pachaikarpoora Vadagam(internal medicine) 1 tablet (500mg0,Bid, with hot water for 48 days in oral route of administration. Vaeppa Ennai (extern

Sponsors

NATIONAL INSTITUTE OF SIDDHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients having symptoms of arthritis of both knee joints, Pain, swelling, stiffness, crepitations, restricted movements of both knee joints. • Patients who are willing to undergo radiological investigation, Laboratory investigations. • Patients willing to sign the informed consent stating that he/she will conscientiously stick to the treatment during 48days but can opt out of the trial of his/her own conscious discretion. • Willing to co operate to take photographs whenever required with his/her consent.

Exclusion criteria

Exclusion criteria: • Cardiac diseases • Diabetes Mellitus • Hypertension • Rheumatoid arthritis • Use of Narcotics • Pregnancy and lactation • History of trauma • Patient with any other serious systemic illness

Design outcomes

Primary

MeasureTime frame
PAIN REDUCTION DETERMINED BY UNIVERSAL PAIN ASSESSMENT SCALE. RESTRICTED MOVEMENT ASSESSMENT SCALE. Timepoint: 48 DAYS

Secondary

MeasureTime frame
REDUCTION OF CLINICAL SYMPTOMSTimepoint: 48 DAYS

Countries

India

Contacts

Public ContactDr Shunmugaram S

National Institute of Siddha

gtsiddha60@gmail.com8056074770

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026